Product image of Memantine Dawa (Memantine Hydrochloride) supplied by GNH India

Memantine Dawa

Active Ingredient:
Memantine Hydrochloride
Origin:
EU

Memantine Dawa (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Memantine Dawa, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and functional abilities.

GNH India supplies Memantine Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Manufacturer / TM Owner

Dawa Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Memantine Dawa is used in the management of neurodegenerative conditions affecting cognition, primarily within the Alzheimer’s disease spectrum.

  • Moderate to severe Alzheimer’s disease: improves cognitive function and daily living activities in affected patients.
  • Dementia associated with Alzheimer’s disease: helps slow the progression of memory loss and functional decline.
  • Behavioral symptoms of Alzheimer’s disease: may reduce agitation, aggression and other neuropsychiatric manifestations.

How It Works

  • Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel at a site distinct from the glutamate binding site, it reduces excessive calcium influx that occurs during pathological glutamate stimulation. This moderates excitotoxic neuronal injury while preserving normal synaptic transmission, thereby supporting neuronal survival and function in patients with Alzheimer’s disease.

Side Effects

Memantine Dawa may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Dizziness
  • Headache
  • Constipation
  • Fatigue

Serious or Rare Side Effects

  • Seizures
  • Severe allergic reactions (e.g., rash, angioedema)
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis
  • Hepatotoxicity (elevated liver enzymes)

Precautions & Warnings

When prescribing Memantine Dawa, clinicians should consider several precautionary measures to ensure safe use.

  • Renal impairment: adjust dose or monitor renal function in patients with reduced clearance.
  • Hepatic impairment: use with caution and assess liver function regularly.
  • History of seizures: monitor closely as the drug may lower seizure threshold.
  • Concomitant NMDA antagonists: avoid combined use to reduce risk of additive CNS effects.
  • Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Memantine Dawa can interact with other medicines, influencing its plasma levels or combined pharmacodynamic effects.

Major Interactions (Avoid)

  • Amantadine: additive NMDA antagonism may increase central nervous system adverse effects.
  • Ketoconazole: strong CYP3A4 inhibition can raise memantine concentrations.
  • Rifampin: potent CYP3A4 induction may reduce memantine exposure.

Moderate Interactions (Monitor Closely)

  • Anticholinergic agents: may diminish the cognitive benefits of memantine.
  • Diuretics: can affect blood pressure and electrolyte balance when combined.
  • Other CNS depressants (e.g., benzodiazepines): may enhance dizziness or sedation.

Frequently Asked Questions

Memantine Dawa is prescribed for the treatment of moderate to severe Alzheimer’s disease and related dementia. It helps improve cognition, memory, and daily functional abilities in patients whose disease has progressed beyond the mild stage.

Memantine Hydrochloride works by blocking the NMDA‑type glutamate receptor in a non‑competitive manner. This reduces excessive calcium entry into neurons during pathological glutamate activity, limiting excitotoxic damage while preserving normal synaptic signaling.

The dosage of Memantine Dawa is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. Physicians typically start with a low dose and may titrate upward, but the exact regimen should follow the prescriber’s instructions.

Safety data for Memantine Hydrochloride in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should only be used when the potential benefit justifies any potential risk to the fetus or infant.

To order Memantine Dawa, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While those agents increase cholinergic activity, memantine targets glutamatergic excitotoxicity. In practice, memantine is often added to an acetylcholinesterase inhibitor for moderate‑to‑severe disease to provide complementary mechanisms of action.

Memantine Dawa should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Memantine Dawa is taken orally, usually with or without food. The tablets should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for seizures, severe allergic reactions such as rash or angioedema, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any signs of these reactions.

Memantine Dawa should be avoided in individuals with known hypersensitivity to memantine or any excipients, and in patients with severe renal impairment where dose adjustment is not feasible. Caution is also advised for those with uncontrolled hypertension or a history of seizures.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Memantine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT